FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
0:00
4:00
Listen to a soundcast of the July 26, 2021 FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
Altri episodi di "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Non perdere nemmeno un episodio di “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)”. Iscriviti all'app gratuita GetPodcast.